Upward Path Session for Cerulean Pharma (CERU); Surprise Bounce-back for NeoPhotonics (NPTN)
Cerulean Pharma Inc. (Nasdaq:CERU) shares soared 54.9% to reach the $3.47 mark early on Wednesday, currently trading at $2.98, up $0.74 (or +33.04%).
There appears to be no particular news from the clinical-stage company that may explain this movement in the stock. Earlier last month. Cerulean Pharma said it is conducting a full strategic review of all alternatives with Aquilo Partners, L.P. as financial advisor, aiming to maximize shareholder value.
Cerulean Pharma, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases, has 27.44M shares outstanding and CERU stock 52-week range is from $0.63 to $4.33 per share.
NeoPhotonics Corp. (NYSE:NPTN) stock plummeted 14% to touch a new 52-week low of $6.90 in early trade Wednesday but moved sharply higher later, currently changing hands at $9.33, up $1.24 (or +15.33%) with 13.46M shares traded so far, representing a large increase in activity versus its average volume (3m) of 1.12M shares.
For the fourth quarter 2016, NeoPhotonics posted revenue of $109.8 million, a 23% increase year over year, and non-GAAP net income of $6.3 million or $0.13 per diluted share, topping the Capital IQ Consensus Estimate of $0.08 earnings per share on revenues of $106.96 million for the period.
According to its business outlook for the first quarter 2017, NeoPhotonics expects revenue in the range of $67 million to $73 million and a non-GAAP net loss of between ($0.20) and ($0.30) per share for the period.
Brokerage firm Needham reiterated a Strong Buy rating on the company’s stock, while reducing its price target from $17.00 to $13.00
NeoPhotonics, which develops, manufactures and markets optoelectronic products that transmit, receive and switch digital optical signals for communications networks, has 42.32M shares outstanding and NPTN stock one-year range is between $6.90 and $18.51 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/